Covers a chemistry-driven binding-to-release strategy that enables targeted payload release from cell-surface receptors without cellular internalization, expanding conjugate targets.
Key Takeaways
- For poorly internalizing targets, drug conjugates dissociate and clear rapidly, limiting efficacy
- This platform demonstrated high specificity from in vitro to clinical specimens
- FAP-BTR-SMDC achieved 5.9-fold higher monomethyl auristatin E exposure (AUC 0–120 h )